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ABSTRACT 
 
Bisphenol A (BPA) is used in the manufacturing of food and beverage containers. 
BPA can leach from the lining of the container to contaminate stored food and drinks, 
and can therefore be consumed by humans. Concerns have been raised that BPA acts as 
an endocrine disruptor of both developmental and reproductive processes. To date several 
nuclear hormone receptors have been shown to be able bind to and be activated by BPA. 
Recent data show that foetuses are more susceptible to BPA exposure, as BPA can 
accumulate in the placenta and high doses of BPA have been measured in umbilical cord 
and amniotic fluid. The potential of BPA exposure to influence body weight has been 
suggested from in vitro studies showing an effect of BPA on adipocyte differentiation 
and lipid accumulation and in vivo rodent studies, showing an association between BPA 
exposure in utero and increased body weight in adulthood. The mechanisms through 
which foetuses and infants are exposed to BPA and the consequences of BPA exposure 
and the onset of obesity are discussed in this chapter. 
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INTRODUCTION 
 
BPA (2,2-bis(4-hydroxyphenyl)propane) is a monomer widely used in the plastics 
industry since the 1950s to manufacture polycarbonate plastics and epoxy resins which line 
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the inside of cans [1]. Today global annual BPA production exceeds 6 billion tonnes [2]. BPA 
is among the most frequent organic wastewater contaminants detected in ground water in the 
USA [3]. In the United States, the median reported BPA concentration in surface waters was 
0.14 μg/L (6.14x10
-4
 μM) whereas in Europe, mean values of 0.0047 μg/L (0.2x10
-4
 μM) and 
0.0052 μg/L (0.23x10
-4
μM) were observed in Germany and Netherlands respectively [4-6]. In 
water near processing facilities, BPA levels can be higher than 20 μg/L (877x10
-4
 μM) [7]. 
Humans are exposed to BPA mainly by consuming contaminated food and drink products. A 
tolerable daily BPA intake (TDI) of 50 µg/kgBW/day has been set by the Environmental 
Protection Agency (U.S. EPA) [8], Food Standards Australia and New Zealand (FSANZ) [9] 
[9] [9] and the European Food Safety Authority (EFSA) [10].  
In the US, measurements of BPA in serum of adult men and women showed that the 
mean concentration of BPA in 2002 was 2.49 ng/mL (109x10
-4
 μM) [11]. In 2011 a study 
showed that subjects consuming a daily serving of canned vegetable soup for 5 days exhibited 
a 1200% increase in urinary BPA concentration compared with controls [12]. 
Almost everyone in the modern world is exposed to BPA. BPA was detected in urine 
samples from 92.6% of the US population studied (National Health and Nutrition 
Examination Survey (NHANES) 2003-2004) [13]. This includes neonates, as BPA is also 
detected in maternal and foetal plasma, in placental tissue in humans [14] and in the milk of 
nursing mothers [15].  
BPA receives scrutiny because it is an estrogenic endocrine disrupting chemical and is 
therefore classified as endocrine disrupter (ED). Historically BPA was classified and only 
suspected to be an estrogenic compound: BPA has been shown in human tissue in vitro to 
bind to and activate the classical estrogen receptors [16] (Figure 1), ERα and ERβ, with a 
lower binding affinity than the natural ligand 17-β estrodial or E2 (10-1000 times lower 
binding affinity) [17, 18] and to the non-classical membrane bound estrogen receptor 
(ncmER) [19] also known as GRP30 [20].  
Although BPA action on insulin secretion via the ER pathway and the onset of diabetes 
has been extensively studied [1, 16, 21], the effects of BPA on obesity are not fully 
understood. Indeed, the available data may point to an antagonistic effect of the ER pathway 
for the onset of diabetes. Hewitt and colleagues investigated a mouse lacking a functional 
aromatase, a crucial enzyme for estrogen biosynthesis, and found that these mice display a 
very low level of estrogen and develop obesity [22].  
This result was also observed in another estrogen deficient mouse lacking follicle-
stimulating hormone (FSH) [23]. Implication of the estrogen pathway was further confirmed 
by the development of obesity in ERα knock-out adult male mice [24]. Interestingly, ERβ 
knock-out adult mice did not show signs of obesity pointing to ERα specificity for 
development of obesity [24]. Therefore it seems that reduced ER activation contributes to the 
development of obesity. As BPA is a known activator of the ERs [25, 26] other protein 
targets for BPA must be examined to understand the possible links between BPA exposure 
and obesity. 
Excessive body weight can be detected very early in life and as pregnant women and 
babies are under constant BPA exposure, the idea that BPA might exert its negative effect 
during foetal life has become increasingly of interest. Recent studies have looked at the 
developmental effects induced by BPA in utero.  
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Figure 1. Chemical structure of BPA and estradiol. Chemical structure of BPA (A) and E2 (B). 
Interaction networks of E2 (C) and BPA (D) with LBP residues in ERα. Oxygen, nitrogen, sulfur, 
fluorine, and chlorine atoms are colored in red, blue, yellow, cyan, and green, respectively. Hydrogen 
bonds are indicated by black dashed lines. For clarity, not all protein–ligand interactions are depicted. 
The blue electron density represents a Fo-Fc simulated annealing omit map contoured at 3σ. (C and D) 
[27]. 
Gibert et al. found that BPA exposure during early zebrafish embryogenesis causes 
otolith (a crystallized structure of the inner hear used for maintaining proper balance) 
malformations [17] and Dong Li et al. determined that BPA exposure during rat 
embryogenesis caused retarded growth in a dose dependant manner, with embryos exhibiting 
hydrocephaly, smaller midbrain, forebrain and forelimb bud, open neural tube and abnormal 
heart, optics and flexion [27]. While these effects found were detectable during development, 
it is hypothesised in regards to metabolic disease, that in utero exposure to BPA may cause 
long term effects that may not be detectable during development or at birth, that increase 
susceptibility to developing metabolic disease later in adulthood. This review will consider 
both the immediate and long term effects of in utero and early life BPA exposure and its long 
term effects on adipogenesis and obesity.  
 
 
Route of BPA Exposure during Early Life 
 
As mentioned, human BPA exposure occurs mainly via the consumption of contaminated 
food and drink. This contamination occurs via the hydrolysis of the ester bonds which link 
BPA to the polycarbonate, allowing for the migration of BPA from the polycarbonate into the 
food or drink it is storing [28]. The BPA migration rate increases with heating [28], prolonged 
storage time and polycarbonate degradation [29]. In addition to BPA exposure via 
consumption, high levels of BPA have also been found in cashiers who handle polycarbonate 
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receipts [30] and in BPA manufacturing workers [31] suggesting BPA exposure may also 
occur via skin contact the respiratory tract.  
Upon oral consumption, BPA is absorbed in the gastrointestinal tract in its free form [32]. 
Some of the free BPA is conjugated to glucuronic acid by the enzyme UDP 
glucuronosyltransferase (UGT). This glucuronation of BPA forms the main BPA metabolite 
BPA-glucuronide, which exhibits no estrogenic activity. The remaining free BPA and BPA-
glucuronide then enter the liver via the portal vein, where it is thought that the majority of 
BPA conjugation takes place by hepatic UGT isoforms [33, 34]. From the liver, free BPA and 
BPA-glucuronide enter the systemic circulation [33]. The conjugation process prior to entry 
to circulation results in low levels of free BPA in adult human plasma, with 17 studies 
between the years 1999-2009 finding serum BPA levels ranging from non-detectable level to 
a highest level of 2.5 ng/ml [35]. Both free BPA and BPA-glucuronide are later excreted via 
the urine [32]. This process of BPA consumption and excretion via the urine has been 
measured to take between 4-42 hours [32, 36]. Interestingly, fasting does not always result in 
rapid decrease in urinary BPA levels, suggesting BPA may be accumulating somewhere in 
the body preventing its rapid excretion [36]. Two tissues suggested to facilitate this BPA 
accumulation are adipose and placental tissue, which will be discusses in more detail later in 
this chapter.  
 
 
Highest Levels of BPA Exposure Occur from Foetal Development to Early 
Childhood 
 
Urinary BPA levels have been used to estimate total BPA exposure levels in different 
population subsets. In 2008, the European Food Safety Authority (EFSA) reported urinary 
BPA exposure levels of: 0.2-13 μg/kgBW/day in infants (3-6 months of age), 5.3 
μg/kgBW/day in children (1.5 years of age) and 1.5 μg/kgBW/day in adults [37]. Chapin et al 
determined similar urinary BPA levels of 1-11 μg/kgBW/day in bottle fed infants (3-6 months 
age), reducing to 0.2-1 μg/kgBW/day in breast fed infants, 1.7-14.7 μg/kgBw/day in children 
and 0.008-1.5 μg/kgBW/day in adults [38]. These data indicate that the highest levels of BPA 
exposure are in infants and children and have recently prompted an increase in the number of 
cross sectional studies which are focusing solely on determining BPA exposure levels in 
children.  
Enabling researchers to extend their study parameters, to not only look at urinary BPA 
levels and body mass index (BMI), but to also include analysis of environmental influences 
that promote obesity. To assist in determining if BPA exposure is associated with obesity 
independent of obesity promoting behaviour, or as a consequence of consuming increased 
levels of BPA contaminated foods. A cross sectional study using 2003-2008 NHANES data 
on children aged 6-19 years found a significant association between higher urinary BPA 
levels and obesity in children, consistent with other studies in adults [39]. Interestingly, this 
study no association between urinary BPA levels and the amount of time spent watching 
television or calorie intake, despite the fact these two factors are associated with obesity [39]. 
The obtained data were able to further support the association of BPA with obesity by finding 
no other environmental phenols other than BPA to be associated with obesity (with the 
exception of one phenol used in sunscreen benzophenone-3, in which they found a 
nonmonotonic relationship, suggesting association was by chance) [39].  
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What is of most concern and the focus of this chapter is early BPA exposure. As in utero 
foetuses are also exposed to BPA, however it is not as simple as determining the mother’s 
BPA exposure level in estimating the amount of BPA to which the foetus is exposed 
throughout development. There is concern that urinary BPA concentrations in pregnant 
women may underestimate the amount of BPA exposure to the developing foetus. As BPA is 
able to readily cross [40] and accumulate in the placenta via binding to the estrogen related 
receptor (ERR)γ [41, 42], which estradiol cannot bind to and for which the natural ligands are 
unknown [43]. There are four ERRs in the human genome: α, β, γ and δ. BPA has the highest 
in vitro binding affinity to ERRγ, which is suggested to play a role in facilitating foetal 
exposure of BPA, as ERRγ is highly expressed in the placenta [41]. 
The strong binding affinity of BPA to ERRγ is suggested to reduce the excretion of BPA 
via the urine. Maternal plasma has been shown to contain 0.3-18.9 ng/ml of BPA (median 3.1 
ng/ml), foetal plasma 0.2-9.2 ng/ml (median 2.3 ng/ml) and placental tissue 1-104.9 ng/ml 
(median 12.7 ng/ml) [14]. Balakrishnan et al used an ex vivo human placental fusion model to 
demonstrate that BPA can cross human placental tissue and that the majority of BPA that 
crosses the placenta is unconjugated [44]. They used an environmentally relevant dose of 10 
ng/ml, similar to the mean BPA level found in placental tissue by Schonfelder et al in 2002 
[14]. The BPA was added to the maternal compartment and within three hours 27% of the 
BPA had transferred to the foetal compartment, less than 10% of which was conjugated [44]. 
This transfer rate of 27% is consistent with knowledge that the median BPA level in placental 
tissue is 12.7 ng/ml and the range of BPA found in umbilical cord blood is 0.5 ng/ml [45] to 
2.59 ng/ml [46].  
The placenta has also been found to contain high levels of the enzyme β-glucuronidase, 
which can free BPA which was previously conjugated to form BPA-glucuronide [47, 48], 
increasing the amount of free BPA that can cross to the foetus (Figure 2). The foetus is more 
vulnerable to the effects of BPA than the mother, as it has an impaired ability to inactivate 
BPA. The BPA conjugating enzyme UGT is present at low levels, in inactive forms or not 
present at all during foetal development, with one study finding no UGT transcripts in the 
foetus up to 20 weeks gestation [49] (Figure 2). BPA exposure is also suggested to reduce 
UGT function, with male Wister rats exposed to 1 mg of BPA for 2 days showing a reduced 
mRNA expression of UGT isoforms [50]. The impaired ability of the foetus to inactivate 
BPA continues through early infant development. The main isoform responsible for 
conjugation of BPA, UGT2B7 increases in activity with age [51]. Edginton and colleagues 
found UGT2B7 to have 5% of maximal activity in newborns, 30% activity at 3 months of age 
and an equal activity to adults by 1 year of age [51]. The difference in the ability of infants, 
children and adults to conjugate BPA before it reaches their plasma was estimated later by the 
same research team of Edginton and Ritter using a physiologically based toxicology model 
scaled to children < 2 years of age. It was estimated an oral dose of 1 μg/kgBW/day of BPA 
would result in newborns to have an 11 fold greater level of free BPA in their plasma and 
children (< 2 years of age) a 5 fold greater level [33] compared with adults. This study 
highlights that the differences between the absorption, distribution, metabolism and secretion 
of BPA in children compared with adults can result in increased plasma levels of BPA in 
children. 
After birth infants continue to be exposed to BPA from potentially every aspect of their 
diet, with BPA found in the mother’s breast milk [1] (up to 1-11μg/kgBW/day [52]), formula 
containers and plastic baby bottles [1] (Figure 2).  
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Figure 2. Route of exposure of BPA to the developing foetus and infant. Adult hepatic conjugation of 
BPA is not sufficient to protect a developing foetus from exposure to free BPA. Due to the placental 
tissue facilitating both the accumulation of BPA via ERRγ and the de-conjugation of BPA via an 
enzyme expressed in placenta tissue, β-glucoronidase. The foetus is particularly vulnerable to the 
effects of BPA due to an impaired ability to conjugate and thus inactivate BPA. After birth the infant 
can then be exposed to BPA via every aspect of its diet, with BPA found in breast milk, formula 
containers and baby bottles. These multiple routes of exposure result in the risk for BPA exposure 
throughout all stages of foetal development and infant life. 
This data showing increased risk of infant compared with adult BPA exposure has 
recently made several countries act in restricting the use of BPA for younger individuals. In 
2012, the US Food and Drug Administration (FDA) banned the use of BPA in the 
manufacturing of baby bottles and sippy cups. This same year the French government banned 
the use of BPA from any products related to infants less than 3 years of age with an extension 
of this ban to cover all food containers from 2015. In the meantime, the plastics industry 
needs to come up with an alternative to BPA. Currently two other bisphenols are being 
studied to replace BPA; bisphenol S and bisphenol AF, which are supposedly less toxic than 
BPA. One of the main issues with these two bisphenols is the lack of data regarding their 
impact on human health. If these two bisphenols are indeed chosen by the plastic industry to 
replace BPA, we can expect more studies in the near future to address this lack of data.  
 
 
BPA Exposure Is Significantly Linked to Obesity 
 
Epidemiological studies show that significantly higher urinary BPA levels have been 
found in obese adults compared to adults of a healthy weight [53]. This was also observed in 
obese children compared with children in the healthy weight range [39]. Obesity is 
characterised by increased size of adipocytes (hypertrophy) and increased number of 
adipocytes (hyperplasia) [54]. It has been argued that these higher levels of BPA in obese 
individuals may be due to the consumption of more high energy foods which are packaged in 
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BPA products, and that BPA is not a direct cause of increased adipocyte hypertrophy and 
hyperplasia. However, it is also possible that early life exposure to increased levels of BPA 
could contribute to the development of obesity. To assist in elucidating if BPA can in fact 
contribute to obesity, the known effects of BPA on adipose tissue are discussed below.  
 
 
BPA Negatively Effects Adipose Function 
 
BPA is a lipophilic compound, with the ability to accumulate in fat [54]. Higher levels of 
BPA have been found in adipocytes (fat cells) of children compared with adults [45]. The 
expression of ERα, ERβ, ERRγ and GPR30 in adipose tissue may facilitate the accumulation 
of BPA in adipose tissue [54]. Adipose tissue functions to store energy and to act as 
endocrine organ. The main type of adipose tissue in humans is white adipose tissue (WAT). 
WAT is composed of adipose derived stem cells such as MSC [55], adipocytes, fibroblasts 
(preadipocytes fated to adipose cell lineage [56]) and immune cells [57]. Adipocytes originate 
from pluripotent mesenchymal stem cells and produce hormones and cytokines involved in 
lipid and glucose metabolism such as; adiponectin, resistin, leptin, TNF-α and IL-6 [58]. 
Disruption of the normal production of these hormones and cytokines is seen in obesity 
(described below) [59]. 
A chronic state of low grade inflammation is seen in obese adipose tissue, with an 
increased presence of IL-6 and TNF-α producing macrophages [60]. In obese adipose tissue 
there are higher levels of free fatty acids (FFAs) released from adipocytes, due to the 
increased number and increased size of adipcoytes. These FFAs bind the toll-like receptor-4 
on the surface of macrophages [61], activating the NF-кB pathway [61] and inducing the 
release of a pro inflammatory cytokine TNF-α [62]. TNF-α has been shown to directly cause 
insulin resistance in adipocytes by inhibiting the insulin signalling pathway [63]. The release 
of TNF-α also promotes increased infiltration of macrophages into adipose tissue by 
activating adipocytes. Activated adipocytes produce IL-6 and monocoyte chemoattractant 
protein-1. IL-6 further increases lipolysis [64] and decreases the production of lipoprotein 
lipase [64, 65] (LPL, an enzyme which releases FFAs from lipoproteins for storage in 
adipocytes) and adiponectin [64, 66] (a hormone that increases insulin sensitivity [67]). MCP-
1 attracts monocytes from the blood into adipose tissue, which differentiate into macrophages. 
BPA has been shown to have similar effects on adipose tissue as obesity. Increasing the 
production of IL-6 and TNF-α in human adipose tissue in vitro [68] and increasing the 
production of a pro inflammatory hormone leptin in vivo in mice [69]. Leptin production is 
significantly increased in obese adipocytes [70] and increased leptin production in adipocytes 
is associated with increased IL-6 and TNF-α [71]. The consequences of increased presence of 
IL-6 and TNF-α in adipose tissue may be the development of inflammation [72]. 
Inflammation of adipose tissue is associated with the increased risk of developing insulin 
resistance and type 2 diabetes [73, 74].  
BPA has been shown to reduce adiponectin release from human adipocytes in vitro [54]. 
Unlike leptin, adiponectin provides protection against inflammation [75], inhibiting the 
activation of NF-кB in macrophages and subsequent IL-6 production. Decreased adiponectin 
levels are associated with obesity [70]. Using mouse 3T3-L1 cells in vitro, Kidani et al. 
showed that BPA may reduce adiponectin release by down regulating the PI3K-Akt signalling 
pathway [76] (insulin activated pathway, which when inhibited results in reduced adiponectin 
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production [77]). Reduced adiponectin release is suggested to contribute to the development 
of insulin resistance as a result of a decrease in the protection it provides against 
inflammation [75, 78].  
 
 
BPA Action on PPARs Leads to Obesity 
 
In addition to negatively affecting adipose function with similar end points as obesity, 
BPA has been shown to increase adipogenesis. Adipogenesis normally occurs in the fed state, 
in which excess free fatty acids (FFAs) from the diet are stored in adipocytes as triglycerol. 
Adipogenesis is promoted by transcription factors such as the peroxisome proliferator-
activated receptor (PPAR)γ, which targets genes involved in fatty acid transport and 
adipocyte differentiation. FFAs are released from lipoproteins (which they are packaged in 
for transport in the blood) by PPARγ activated lipoprotein lipase (LPL). FFAs are then re-
esterified to form triglycerol and transported into adipocytes [79]. In a starved state the 
triglycerol can be a source of energy, released from the adipocytes by lipolysis. As well as 
excess FFAs from the diet causing hypertrophy of adipocytes, the presence of preadipocytes 
[80, 81] and mesenchymal stem cells in adipose tissue suggests that these FFAs may also be 
stored in newly differentiated adipocytes, which increase the number of adipocytes, 
contributing to the development of obesity.  
Known natural ligands for PPARγ include the unsaturated fatty acids; oleate, linoleate, 
eicosapentaenoic and arachiodonic acids [82]. Activated PPARγ, acts by forming an obligate 
heterodimer with retinoid X receptor (RXR). This heterodimer binds peroxisome proliferator-
activated response elements (PPREs) which are present in the promoter region of genes 
involved in promoting adipogenesis and fatty acid transport such as; PEPCK, LPL and ap2 
[83], a fatty acid binding protein involved in fatty acid transport [84]. PPARγ also increases 
activity of acetyl-Co-synthetase and the re-esterification of fatty acids [79].  
Recently, BPA has been shown to be unable to act as a ligand of PPARγ. Riu et al 
showed that BPA is unable to activate PPARγ in HGLEN-PPAR cells [85] and Chamorro-
Garcia and colleagues showed that BPA cannot activate PPARγ in COS7 cells [86]. However, 
BPA has been shown to increase PPARγ activity in vitro in human adipocytes [87] and in 
vivo in rats [69]. It is hypothesised that BPA may increase PPARγ activity levels by activating 
components of the MAPK pathway [88]. Adipose tissue from children aged 3-13 years treated 
with 10 nM BPA in vitro showed increased mRNA expression of PPARγ and 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme which activates cortisone and 
promotes adipogenesis [87]. Sprague-Dawely rats exposed to BPA via their mothers placenta 
and breast milk from gestational day 6 to the end of lactation showed significantly increased 
levels of WAT at postnatal day 21 that expressed greater levels of PPARγ mRNA compared 
with control offspring [69]. These data suggest that although BPA cannot bind PPARγ, it is 
able to increase PPARγ production and adipogenesis thus highlighting the potential for BPA 
to act as an obesogen, increasing the risk of developing obesity. 
BPA has also been shown to increase adipogenesis by increasing insulin induced 
triglyceride accumulation [89]. Combined treatment of 20 ng/ml BPA (875x10
-4
 µM) and 
insulin (5 ng/ml) accelerated the conversion of mice 3T3-L1 cells into adipocytes in vitro 
[89], increasing the percentage differentiated cells from 28% in insulin treated to 83% in 
insulin plus BPA treated [89]. These differentiated cells showed a 13,000% increase in 
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triglyceride (TG) content, a 190% increase in LPL activity and a 3.3-fold increase in the 
activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [89]. This effect of BPA on 
increasing LPL activity and adipocyte differentiation in 3T3-L1 cells was not supported in a 
study using Human Adult Stem Cells (hASC) [90], in which treatment with 80 μM BPA had 
the opposite effect, reducing LPL expression by 70% [90]. This reduction in LPL was not due 
to decreased cell viability from the treatment and did not alter the percentage of hASCs which 
committed to the adipose cell lineage [90]. The clinical implications of reduced LPL 
production in humans could be an increase in circulating FFAs in the blood stream which 
may accumulate in other organs such as liver and skeletal muscle instead of being deposited 
into adipocytes leading to a higher risk of insulin resistance and type 2 diabetes [90] (Figure 
3). 
 
 
Figure 3. Schematic representation of genes and pathways involved in obesity that can be influence by 
BPA exposure. BPA exposure may increase body weight via three main mechanisms; decreasing 
normal adipose function, resulting in increased TG storage. Promoting adipogenesis, resulting in 
increased adipocyte numbers and therefore increased ability for TG storage. And via altering 
metabolism, decreasing insulin sensitivity and glucose tolerance, resulting in hyperinsulinemia and an 
inability to sufficiently lower blood glucose levels. 
Halogenated forms of BPA are able to bind and activate PPARγ. Halogenated BPAs have 
been detected in human tissues; human plasma [91], urine [92], umbilical cord blood [93] and 
breast milk [93, 94]. Riu et al demonstrated the flame retardants Tetrabromobisphenol A 
(TBBPA) and tetrachlorobisphenol A (TCBPA) can act as a ligand for PPARγ in vitro, and 
that 10 μM of these halogenated BPA analogues increased adipocyte differentiation and 
PPARγ mRNA expression levels in 3T3-L1 preadipocytes [85]. Co treatment with a PPARγ 
antagonist CD5477, prevented the halogenated BPAs from increasing adipocyte 
differentiation in 3T3-L1 preadipocytes, suggesting TBBPA and TCBPA are acting via 
PPARγ [85]. While the ability for TBBPA and TCBPA to activate PPARγ was found to be 
100 fold less than rosiglitazone, TBBPA and TCBPA are 10-100 times more potent at 
activating PPARγ than other well-known PPARγ ligands; PFOA, PFOS and MEHP [85].  
Another BPA halogen, Bisphenol A diglycidyl ether (BADGE) used in the production of 
epoxy resins, has also been shown to increase adipogenesis in 3T3-L1 preadipocytes, as well 
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as in mice and human mesenchymal stromal stem cells (MSCs) [86]. Unlike TBBPA and 
TBBPA, BADGE cannot activate PPARγ, having no agonistic or antagonistic activity to 
PPARγ [86]. Hypothesising instead that BADGE is acting downstream or parallel to PPARγ 
[86] to increase adipogensis. In this study, BPA like BADGE, also induced adipocyte 
differentiation in the 3T3-L1 preadipocytes, consistent with previous studies [89, 95, 96], 
however unlike BADGE, BPA was unable to induce adipogenesis in the human and mice 
MSCs [86]. This suggests that BPA may only induce adipocyte differentiation in cells already 
fated to the adipocyte cell lineage. This finding is consistent with a previous study which 
found BPA to have no effect on adipocyte differentiation in hASC [90], which are also yet to 
be fated to the adipocyte cell lineage.  
The ability of BPA and halogenated BPAs to increase the activity of PPARγ indirectly 
and directly respectively highlights the ability of these environmental contaminants to 
increase the rate of adipogenesis. In addition, the ability of BADGE to act on MSCs which 
have yet to commit to a cell lineage, suggests that exposure to halogenated forms of BPA 
during early development may increase the number of preadipocytes which can store 
triglycerol later in life, contributing to the development of obesity.  
 
 
BPA and Glucocorticoid Receptor in Obesity 
 
Recently a new binding target has emerged in the world of BPA, the glucocorticoid 
receptor (GR). Using in silico analysis, Prasanth and colleagues showed that BPA could 
successfully dock into the ligand binding pocket of human GR [97]. By comparing to the 3D 
structure of cortisol and dexamethasone bound to the GR the authors found that BPA had a 
similar mode of interaction and binding energy as these two known GR agonists. Therefore 
Prasanth et al concluded that BPA is able to bind GR as an agonist and may be able to 
produce similar biological effects as natural or synthetic glucocorticoids [97]. Although this 
study was in silico, the data support the idea that BPA can bind to and activate the human GR 
and therefore BPA exposure might reproduce the glucocorticoids induced phenotype. 
Activation of the GR plays an important role in adipocyte differentiation [98]. 
Glucocorticoids (GCs) are also well known for their role in appetite regulation. GCs can 
stimulate food intake via different mechanisms: they stimulate the action of two orexigenic 
(appetite stimulant) peptides: NPY and agouti related peptide (AGRP) [5]. Moreover GCs 
also reduce the sensitivity of the brain to leptin, an anorexigenic (appetite suppressor) peptide, 
leading to general leptin resistance [99]. As it has recently been shown that appetite 
regulating gene expression can be modulated during embryonic development in absence of 
active feeding [100], it is easy to speculate the activation of the GC pathway by circulating 
BPA either in the mother’s blood or in the foetus might impact the expression of these 
appetite regulating genes and affect the feeding behaviour of the new born baby. Several 
observations tend to confirm this hypothesis. For example prenatal stress is associated with 
long term susceptibility to obesity [101]. This is most likely achieved through altered 
corticosterone levels in the adult offspring [102] and reduced hippocampal levels of 
mineralocorticoid receptor and GR [103]. Therefore if, as suspected, BPA is an agonist of GR 
[97], foetal exposure to BPA will have long term consequences in the adult life of the 
exposed foetus. It should to be noted however that these observations came from rodents and 
have not yet been proven in humans.  
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What is known about human obesity and GR comes predominantly from diseases 
associated with altered GC levels. Cushing’s syndrome patients have high levels of cortisol 
[104]. One of the main symptoms associated with this disease is the rapid weight gain, 
particularly in the upper body and the face. On the other hand, patients suffering from 
Addison’s disease, which is characterized by hypocortisolism (low level of cortisol), 
experience weight loss [105]. Therefore the link between obesity and the GR pathway is clear 
in humans. It has now to be investigated if BPA exposure acting through the GR could lead to 
weight gain in humans. As more and more data points to the fact that BPA target a wider 
range of nuclear receptors, future studies will help to confirm the putative link between BPA 
and the GR pathway in weight gain and obesity.  
 
 
In Utero Exposure to BPA in Rodents Has Variable Effects on Offspring 
Body Weight 
 
It is hypothesised that the effects of BPA are not limited to immediate changes in adipose 
function and that short term exposure to BPA in utero may increase susceptibility to obesity 
later in adulthood [106]. Studies to date using rodents have shown variable effects on the 
body weight of offspring from pregnant rodents exposed to BPA throughout gestation and/or 
lactation. Some offspring exhibited increased [69, 107-110], decreased [108, 109, 111] or no 
changes [110, 112-114] in body weight compared with control offspring (Table 1). Effects of 
in utero exposure on the expression of adipogenesis markers and adipose function have also 
been variable. The variability in these studies may be due to the choice of animal model used, 
the litter size and the dose, route and duration of BPA exposure [115].  
Somm et al. found that Sprague-Dawley rats exposed to BPA during gestation and 
lactation developed metabolic abnormalities that were detectable from birth to 6 months of 
age [69]. In their study pregnant Sprague-Dawley rats were exposed to 1 ng/ml of BPA via 
their drinking water from gestational day 6 (GD6) to postnatal day 21 (PND21) [69]. While 
the average level of maternal BPA exposure was estimated to be 70 μg/kgBW/day, this level 
is still considered a low dose and the route of exposure used in this study mimics the human 
route of exposure to BPA. Studies using subcutaneous injection result in BPA entering 
circulation before being partially inactivated by UGT in the liver, resulting in an increased 
plasma level of unconjugated BPA than would have been present using the same dose via an 
oral route [116]. Another advantage of the study design was the exposure of BPA throughout 
gestational day 6 until the end of lactation, as it is known that BPA exposure is not limited to 
in utero development, with BPA exposure continuing after birth via both breast milk and 
formula containers.  
Somm et al found both male and female pups exposed to BPA throughout gestation 
showed a significantly higher birth weight than control pups (p< 0.05, n=47-50) [69]. After 
weaning only females showed a significantly higher body weight than controls (p< 0.001, 
n=26-32) [69].  
These females at postnatal day 21 had increased WAT mass with hypertrophy of 
adipocytes, and had up to two fold increase in mRNA expression levels of transcription 
factors that promote adipogenesis; C/EBP-α, PPAR-γ, SREBP-1C (p< 0.002) and 
significantly increased mRNA expression levels of LPL (p< 0.05) (Figure 3). 
 Table 1. BPA exposure and change in weight 
 
Reference 
Strain of 
animal 
Dose and route of 
exposure 
Duration of BPA 
exposure 
Diet after weaning 
BPA exposed offspring weight compared to 
control 
Change in 
mothers weight 
 
Increase in offspring weight  
 
[69] Sprague-
Dawley rats 
Orally 1 mg/ml 
BPA in drinking 
water, 70 
μg/kgBW/day 
 
GD6 – end of 
lactation 
n/a BPA exposed males increased birth weight 7.33 ± 
0.12 g, n = 45 compared to control 6.91 ± 0.15 g, 
n = 55,  
p=< 0.05. BPA exposed females increased birth 
weight 7.03 ± 0.11 g, n = 50 compared to control 
6.47 ± 0.12 g,  
n = 47, p =< 0.001 and increased weight at 
PND21, 53.73 ± 0.65 g, n = 32 compared to 
controls 47.79 ± 1.44 g,  
n = 26, p=< 0.001. 
 
No change during 
or 6 months after 
pregnancy 
compared to 
control 
[107] CRI mice Orally 1 μg/ml BPA 
in drinking water, 
0.26 mg/kgBW/day  
GD10 – PND31  Calories from 
protein; 15%, fat; 
30%, carbohydrate 
55% + continued 
BPA in drinking 
water 
PND21-PND31 
 
BPA exposed males (n=25) 22% increased 
weight compared to control (n=23) at PND31 
(p=<0.01).  
BPA exposed females (n=16) 13% increased 
weight compared to control (n=19) at PND31 
(p=<0.05). 
 
Not specified 
 Orally 10 μg/ml 
BPA in drinking 
water, 2.72 
mg/kgBW/day 
GD10 – PND31 Calories from 
protein; 15%, fat; 
30%, carbohydrate 
55% + continued 
BPA in drinking 
water 
PND21-PND31 
 
BPA exposed males (n=19) 59% increased body 
weight compared to control (n=23) at PND31 
(p=<0.05). 
BPA exposed females (19) 11% increased body 
weight compared o control (n=19) at PND31 
(p=<0.05) 
Not specified 
[108] ICR mice Orally via injection,  
50 mg/kgBW/day 
 
GD6-PND21 Soy free diet BPA exposed males increased weight compared 
to control on PND21 (n=10 per group, p=0.05) 
 
Not specified 
 
 Reference Strain of animal 
Dose and route of 
exposure 
Duration of 
BPA exposure 
Diet after weaning BPA exposed offspring weight compared to control 
Change in 
mothers weight 
[109] OF-1 mice Subcutaneous injection , 
10 μg/kgBW/day 
GD6-16 Calories from 
protein; 20%, fat; 
13%, carbohydrates; 
67% 
BPA exposed male and female offspring had 
increased weight at birth and weaning compared to 
controls 3% and 7% respectively (n=25-60 per group, 
p=<0.05). 
 
Increased weight 
measured at 3 and 
4 month after 
pregnancy 
[110] Wister rats Oral gavage,  
50 μg/kgBW/day 
GD0-PND21 Normal diet, calories 
from protein; 25%, 
fat 12%, 
carbohydrates; 63% 
BPA exposed males increased weight compared to 
control from 19 weeks (n=10 per group, p=<0.05) 
BPA expose females increased weight compared to 
control from 17 weeks (n=10 per group, p=<0.05) 
 
Not specified  
    High fat diet, calories 
from protein; 22%, 
fat 29%, 
carbohydrates; 49% 
BPA exposed males increased weight compared to 
control from 7 weeks (n=10 per group, p=<0.05). 
BPA exposed females increased weight compared to 
control from 9 weeks (n=10 per group, p=<0.05). 
Not specified  
Decrease in offspring weight  
[111] ICR/jcl mice Subcutaneous injection 
2 μg/kgBW/day 
GD11-GD17 CE-2, CLEA, Tokyo, 
Japan 
 
BPA exposed females decreased weight at PND22, 
15.6 ± 0.8g, compared to control 17.3 ± 0.5 g, n=10 
per group, p < 0.05. 
Not specified 
  Subcutaneous injection 
20 μg/kgBW/day 
  BPA exposed males decreased weight at PND1, 1.81 
± 0.03g, compared to control 1.91 ± 0.01 g, p < 0.05 
and at PND60, 40.9 ± 0.9g, compared to control 43.3 
± 0.6 g, n=1-0 per group, p < 0.05. Females decreased 
weight at PND22, 16.1 ± 0.8g, compared to control 
17.3 ± 0.5 g, p < 0.05 and at PND60, 32.3 ± 1.1 g, 
compared to control 33.7 ± 0.9 g, n=10 per group, p < 
0.05. 
Not specified  
[109] OF-1 mice Subcutaneous injection , 
10 μg/kgBW/day 
GD6-16 Calories from 
protein; 20%, fat; 
13%, carbohydrates; 
67% 
BPA exposed female offspring 3% decreased weight 
compared to controls at 3 months of age (n=25-60 per 
group, p=<0/05) 
Increased weight 
measured at 3 and 
4 month after 
pregnancy 
  Subcutaneous injection , 
100 μg/kgBW/day 
  BPA exposed male and female offspring had 
decreased weight at birth and weaning compared to 
controls of 4.5% (p=<0.05). BPA exposed female 
offspring 2.5% decreased weight compared to 
controls at 3 months of age (n=25-60 per group, 
p=<0/05) 
Increased weight 
measured at 3 and 
4 month after 
pregnancy 
 Table 1. (Continued) 
 
Reference Strain of animal 
Dose and route of 
exposure 
Duration of 
BPA exposure 
Diet after weaning BPA exposed offspring weight compared to control 
Change in 
mothers weight 
[108] ICR mice Orally via injection,  
0.05 mg/kgBW/day 
GD6-PND21 Soy free diet BPA exposed males decreased weight on PND21 and 
PND56 compared to controls (n=10 per group, 
p=0.05) 
 
Not specified 
  Orally via injection,  
0.5 mg/kgBW/day 
  BPA exposed males decreased weight PND56 
compared to controls (n=10 per group, p=0.05) 
 
 
No change in offspring weight  
[112] Sprague dawley 
rats 
Orally via diet 
0.017, 0.17 and 1.7 
mg/kgBW/day 
GD6-PND21 Normal diet ad 
libitum 
No overall changes (temporary changes in weight 
seen for only 1 or 2 weeks compared to controls, 
measurements taken from birth to 13 weeks). 
 
No change during 
gestation or 
lactation  
[113] Wister rats Orally 10 mg/L in 
drinking water,  
1.2 mg/kgBW/day 
GD6- day 21 
of lactation 
Not specified No change (measurements taken from birth to 3 
months of age). 
 
Not specified  
[110] Wister rats Oral gavage,  
250 and 1250 
μg/kgBW/day 
GD0-PND21 Normal diet, calories 
protein; 25%, fat 
12%, carbohydrates; 
63% 
No change (measurements taken from birth to 28 
weeks) 
Not specified  
    High fat diet, calories 
protein; 22%, fat 
29%, carbohydrates; 
49% 
 
No change (measurements taken from birth to 28 
weeks) 
Not specified  
[114] Long-Evans rats Oral gavage 
2, 20 and 200 
μg/kgBW/day 
GD7-PND18 Purina rat show 5001 No change (measurements taken from PND2 No change during 
gestation or 
lactation 
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These data are consistent with the in vitro increase in LPL activity in BPA treated 3T3-
L1 cells [69] and in human adipocytes [87], and the in vitro increase in PPARγ mRNA 
expression in BPA treated human adipocytes [87]. From weeks 4-14 the pups were then fed 
either a normal or high fat diet containing no BPA. There were no differences in energy 
intake between pups exposed to BPA in utero and control pups on either diet [69]. Male pups 
exposed to BPA in utero showed a significant increase in body weight compared with 
controls on the high fat diet [69]. Female pups exposed to BPA in utero showed significant 
increases in body weight compared to controls on both normal and high fat chow diets [69]. 
Therefore, in utero exposure to BPA may have long term effects on the susceptibility of 
developing obesity. 
The pregnant Sprague-Dawley rats drinking the BPA water exhibited no change in body 
weight or metabolic profile throughout gestation and lactation [69]. This was an important 
factor to consider to eliminate defects in the mothers ability to maintain glucose homeostasis 
which may affect the offspring’s development throughout gestation and lactation as well as 
later in life. Offspring from obese or glucose intolerant mothers have significant increased 
risk of developing obesity later in life [117]. This study suggests that although adult human 
exposure levels to BPA are low, exposure to BPA exclusively in utero and during early infant 
development via a healthy mother’s placenta and breast milk may be sufficient to increase the 
susceptibility to developing obesity later in life.  
 
 
In Utero Exposure to BPA in Humans Is Significantly Linked to Decreased 
Birth Weight 
 
In humans the birth weight of infants from parents who work in BPA manufacturing and 
in a non BPA industry were compared [118]. Those parents working in BPA manufacturing 
had a higher level of BPA exposure compared with parents working in a non BPA industry 
[118]. Data from a previous study showed a mean 48-fold increase in urinary BPA levels in 
BPA manufacturing workers compared to workers from non BPA industries [31]. Infants 
from mothers with the higher levels of BPA exposure (n=46) had significantly lower birth 
weight compared with infants from mothers with lower BPA exposure (p=0.02) [118]. These 
findings were consistent with another study which used ultrasonography to measure foetal 
development, finding BPA exposure to be correlated with decreased foetal head, femur and 
abdominal circumference [119]. However another study found no correlation between infant 
birth weight from mothers exposed to higher BPA levels ranging from 0.5 to 22.3 ng/ml 
[120]. Therefore it is still unclear if pregnant mothers exposed to BPA will give birth to 
infants with a quantifiable decreased birth weight.  
The first prospective study in humans looking at in utero BPA exposure and the 
development of obesity later in life has been published [121]. Data from this study shows a 
significant association between higher levels of utero BPA exposure and lower body weight 
in females at ages 6-9 years [121]. Contrary to the hypothesis that in utero BPA exposure is 
promoting obesity. However, it will be of interest to see the outcome of this study once 
participants have reached adulthood. As it is difficult to compare the current collected data 
from this study with available data from animal studies, due to the fact many rodent studies 
looking at in utero BPA exposure only see an onset of increased body weight in adulthood, 
which may also be true for humans.  
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Determining any long term effects of in utero BPA exposure is made difficult not only by 
the strong environmental influence of diet and lifestyle in the development of obesity 
regardless of any presence of BPA, but also the lack of available long term data showing 
levels of BPA exposure from utero to adulthood. While animal studies therefore play an 
important role in determining the extent of the effect, if any BPA may have in the 
development of obesity. The variability seen in rodent studies makes it difficult not only to 
determine the role BPA may have in the development of obesity in rodents, but to also then 
correlate these findings to humans.  
 
 
CONCLUSION 
 
The data discussed in this chapter suggest that BPA acting early in life may have 
implications on obesity and adipose capacity later in life, for example by increasing the 
number of adipocyte precursors. Although BPA is one of the most studied endocrine 
disrupters, a lot remains to be elucidated regarding this compound, especially when dealing 
with obesity, but with more and more studies in silico, in vitro, in several animal models, and 
in epidemiological studies, the years ahead should give answers regarding the effects of early-
life exposure to BPA and their links with metabolic syndromes. 
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